Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$27.15
-3.5%
$32.81
$26.25
$42.48
$13.92B0.644.48 million shs2.03 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$720.64
0.0%
$838.96
$677.09
$972.53
$682.51B0.513.37 million shs1.11 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
-8.66%-10.20%-21.52%-4.37%-33.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-4.23%-8.72%-12.63%-9.95%-5.43%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.5222 of 5 stars
3.24.01.74.01.31.72.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9692 of 5 stars
4.45.03.34.02.72.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.40
Hold$38.5642.03% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.89
Moderate Buy$1,017.6741.22% Upside

Current Analyst Ratings Breakdown

Latest BAX and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,146.00 ➝ $1,124.00
4/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$892.00 ➝ $888.00
3/10/2025
Baxter International Inc. stock logo
BAX
Baxter International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$39.00 ➝ $41.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/26/2025
Baxter International Inc. stock logo
BAX
Baxter International
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Buy$42.00
2/24/2025
Baxter International Inc. stock logo
BAX
Baxter International
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
2/21/2025
Baxter International Inc. stock logo
BAX
Baxter International
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$38.00 ➝ $36.00
2/20/2025
Baxter International Inc. stock logo
BAX
Baxter International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$39.00
2/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00
(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$10.64B1.31$4.21 per share6.45$16.69 per share1.63
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.17$11.75 per share61.34$15.05 per share47.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
-$649M-$1.28N/A9.940.93-5.05%16.67%4.93%5/1/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7161.4723.161.4023.51%85.24%16.19%5/1/2025 (Estimated)

Latest BAX and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Baxter International Inc. stock logo
BAX
Baxter International
$0.48N/AN/AN/A$2.59 billionN/A
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
2/20/2025Q4 2024
Baxter International Inc. stock logo
BAX
Baxter International
$0.52$0.58+$0.06-$1.00$2.67 billion$2.75 billion
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$0.682.50%-1.40%N/A N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.83%+15.21%51.24%11 Years

Latest BAX and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/11/2025
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.172.22%2/28/20252/28/20254/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.31
1.43
1.09
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
60,000512.92 million509.47 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable

Recent News About These Companies

Eli Lilly to recognize $1.57B in Q1 as acquired R&D charges
Eli Lilly and Company stock logo
Promising Pharmaceutical Stocks To Consider - April 9th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Baxter International stock logo

Baxter International NYSE:BAX

$27.15 -0.99 (-3.53%)
As of 12:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$720.64 -0.27 (-0.04%)
As of 12:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.